Eli Lilly and Company

Scottsdale, Arizona

OncologyFiled/ApprovedListed · LLY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

What changed

Phase I trial registered: A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

yesterdayTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE3 registered
Jul 1, 2026
Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders, Nutritional and Metabolic Diseases, Endocrine System Diseases, Feeding Behavior, Behavior, Fasting, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide Receptors, Receptors, G-Protein-Coupled, Receptors, Cell Surface, Membrane Proteins, Proteins, Receptors, Peptide · NOT_YET_RECRUITING · sponsor: Eli Lilly and Company · A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
ClinicalTrials.gov · NCT07613307 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jun 1, 2026
Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a) · RECRUITING · sponsor: Eli Lilly and Company · A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
ClinicalTrials.gov · NCT07613294 (opens the source filing in a new tab)
Trial
PHASE2 registered
May 13, 2026
Breast Neoplasms · RECRUITING · sponsor: Eli Lilly and Company · A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
ClinicalTrials.gov · NCT07287098 (opens the source filing in a new tab)
Trial
PHASE1 registered
Apr 21, 2026
Healthy · RECRUITING · sponsor: Eli Lilly and Company · A Study of Eltrekibart (LY3041658) in Healthy Participants
ClinicalTrials.gov · NCT07545590 (opens the source filing in a new tab)
Trial
PHASE1 registered
Apr 17, 2026
Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma · RECRUITING · sponsor: Eli Lilly and Company · A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
ClinicalTrials.gov · NCT07226843 (opens the source filing in a new tab)
Trial
PHASE1 registered
Mar 18, 2026
Obesity, Overweight · ACTIVE_NOT_RECRUITING · sponsor: Eli Lilly and Company · A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
ClinicalTrials.gov · NCT07476118 (opens the source filing in a new tab)
Trial
PHASE4 registered
Mar 9, 2026
Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic · RECRUITING · sponsor: Eli Lilly and Company · A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ClinicalTrials.gov · NCT07218341 (opens the source filing in a new tab)
Trial
PHASE2 registered
Feb 13, 2026
Opioid Use Disorder · RECRUITING · sponsor: Eli Lilly and Company · A Study of Brenipatide in Participants With Opioid Use Disorder
ClinicalTrials.gov · NCT07420283 (opens the source filing in a new tab)
Trial
PHASE3 registered
Dec 22, 2025
Breast Neoplasms, Neoplasm Metastasis · RECRUITING · sponsor: Eli Lilly and Company · A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
ClinicalTrials.gov · NCT07174336 (opens the source filing in a new tab)
Trial
PHASE3 registered
Nov 17, 2025
Obesity, Overweight · ACTIVE_NOT_RECRUITING · sponsor: Eli Lilly and Company · A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
ClinicalTrials.gov · NCT07232719 (opens the source filing in a new tab)
Trial
PHASE3 registered
Oct 15, 2025
Metabolic Dysfunction-Associated Steatotic Liver Disease · RECRUITING · sponsor: Eli Lilly and Company · A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
ClinicalTrials.gov · NCT07165028 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jul 21, 2025
Healthy · TERMINATED · sponsor: Eli Lilly and Company · A Study of LY3549492 in Healthy Weight Adult Participants
ClinicalTrials.gov · NCT07085468 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jun 23, 2025
Healthy · COMPLETED · sponsor: Eli Lilly and Company · A Study of [14C]-LY4065967 in Healthy Participants
ClinicalTrials.gov · NCT07039045 (opens the source filing in a new tab)
Trial
PHASE3 registered
May 19, 2025
Obesity, Overweight, Type 2 Diabetes · ACTIVE_NOT_RECRUITING · sponsor: Eli Lilly and Company · A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
ClinicalTrials.gov · NCT06972472 (opens the source filing in a new tab)
Trial
PHASE1 registered
Apr 9, 2025
Overweight, Obesity · COMPLETED · sponsor: Eli Lilly and Company · A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
ClinicalTrials.gov · NCT06916065 (opens the source filing in a new tab)
Trial
PHASE1 registered
Dec 13, 2024
Healthy · COMPLETED · sponsor: Eli Lilly and Company · A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
ClinicalTrials.gov · NCT06692348 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jan 12, 2024
Prostatic Neoplasms · TERMINATED · sponsor: Eli Lilly and Company · Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
ClinicalTrials.gov · NCT05999968 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jul 5, 2022
Hepatic Insufficiency, Healthy · COMPLETED · sponsor: Eli Lilly and Company · A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
ClinicalTrials.gov · NCT05440344 (opens the source filing in a new tab)
Trial
PHASE3 registered
Apr 14, 2022
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 · ACTIVE_NOT_RECRUITING · sponsor: Eli Lilly and Company · A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
ClinicalTrials.gov · NCT05288166 (opens the source filing in a new tab)
Trial
PHASE3 registered
Dec 21, 2021
Covid19, Corona Virus Infection · TERMINATED · sponsor: Eli Lilly and Company · A Study of Baricitinib (LY3009104) in Children With COVID-19
ClinicalTrials.gov · NCT05074420 (opens the source filing in a new tab)
Trial
PHASE1 registered
Oct 8, 2020
Diabetes Mellitus, Type 2 · COMPLETED · sponsor: Eli Lilly and Company · A Study of LY3502970 in Participants With Type 2 Diabetes
ClinicalTrials.gov · NCT04426474 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jun 11, 2020
Neuroblastoma · ACTIVE_NOT_RECRUITING · sponsor: Eli Lilly and Company · A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
ClinicalTrials.gov · NCT04106219 (opens the source filing in a new tab)
Trial
PHASE3 registered
Mar 14, 2018
Episodic Migraine · ACTIVE_NOT_RECRUITING · sponsor: Eli Lilly and Company · A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
ClinicalTrials.gov · NCT03432286 (opens the source filing in a new tab)
Trial
PHASE1 registered
Dec 18, 2017
Healthy Adult Subjects · COMPLETED · sponsor: Eli Lilly and Company · A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
ClinicalTrials.gov · NCT03381547 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 1.00{"reasons":["name similarity 100%","semantic similarity 80%","shared principal investigator / founder","same city","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.95{"reasons":["name similarity 100%","semantic similarity 84%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.95{"reasons":["name similarity 100%","semantic similarity 82%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.95{"reasons":["name similarity 100%","semantic similarity 82%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.93{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.93{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.92{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
new_entity links the trial record at 0.50{"reasons":["name similarity 100%"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase I trial registered: A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
yesterdayTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
yesterdayTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
yesterdayTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
yesterdayTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
yesterdayTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
yesterdayTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
yesterdayTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
yesterdayTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
2d agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
1w agoTrial completedSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Study of Brenipatide in Participants With Opioid Use Disorder
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Brenipatide in Participants With Opioid Use Disorder
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
2w agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
3w agoTrial registeredSource (opens the source filing in a new tab)
Filed/Approved trial registered: A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
3w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
3w agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Study of Eltrekibart (LY3041658) in Healthy Participants
3w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Eltrekibart (LY3041658) in Healthy Participants
3w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
3w agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study of LY3502970 in Participants With Type 2 Diabetes
7w agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of LY3502970 in Participants With Type 2 Diabetes
7w agoTrial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
3mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
5mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
5mo agoTrial completedSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
5mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Baricitinib (LY3009104) in Children With COVID-19
7mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
8mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
8mo agoTrial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study of [14C]-LY4065967 in Healthy Participants
10mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of [14C]-LY4065967 in Healthy Participants
10mo agoTrial completedSource (opens the source filing in a new tab)
Phase II trial registered: A Study of LY3549492 in Healthy Weight Adult Participants
10mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
Jun 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
Jun 2025Trial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE3 registered

PHASE3 registered

PHASE2 registered

PHASE1 registered

PHASE1 registered

PHASE1 registered

PHASE4 registered

PHASE2 registered

PHASE3 registered

PHASE3 registered

PHASE3 registered

PHASE2 registered

PHASE1 registered

PHASE3 registered

PHASE1 registered

PHASE1 registered

PHASE1 registered

PHASE1 registered

PHASE3 registered

PHASE3 registered

PHASE1 registered

PHASE1 registered

PHASE3 registered

PHASE1 registered